| Date Checked | 2025-12-21 23:26:11 |
|---|---|
| Graham Number | (PB)175.10 vs (PE)62.71 |
| Over / Under Value Percentage | -7.23% vs 56.96% |
| Dividend Yield | 0.00% |
| Dividend Date | None |
| Symbol | BIIB |
| AssetType | Common Stock |
| Name | Biogen Inc |
| Description | Biogen Inc. is a prominent biotechnology company headquartered in Cambridge, Massachusetts, specializing in the discovery and development of groundbreaking therapies for neurological disorders. With an extensive pipeline targeting significant conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, Biogen is positioned as a critical player in addressing substantial unmet medical needs in the healthcare landscape. The company's focus on advancing therapeutic innovation is complemented by strategic collaborations and a strong commitment to scientific research, underscoring its leadership within the biotechnology sector and dedication to enhancing patient outcomes globally. |
| CIK | 875045 |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | DRUG MANUFACTURERS - GENERAL |
| Address | 225 BINNEY STREET, CAMBRIDGE, MA, UNITED STATES, 02142 |
| OfficialSite | https://www.biogen.com |
| FiscalYearEnd | December |
| LatestQuarter | 2025-09-30 |
| MarketCapitalization | 25643557000 |
| EBITDA | 3409300000 |
| PERatio | 15.92 |
| PEGRatio | 4.942 |
| BookValue | 124.11 |
| DividendPerShare | None |
| EPS | 10.98 |
| RevenuePerShareTTM | 68.81 |
| ProfitMargin | 0.16 |
| OperatingMarginTTM | 0.307 |
| ReturnOnAssetsTTM | 0.0575 |
| ReturnOnEquityTTM | 0.0931 |
| RevenueTTM | 10065900000 |
| GrossProfitTTM | 7706800000 |
| DilutedEPSTTM | 10.98 |
| QuarterlyEarningsGrowthYOY | 0.192 |
| QuarterlyRevenueGrowthYOY | 0.028 |
| AnalystTargetPrice | 180.69 |
| AnalystRatingStrongBuy | 2 |
| AnalystRatingBuy | 14 |
| AnalystRatingHold | 19 |
| AnalystRatingSell | 0 |
| AnalystRatingStrongSell | 0 |
| TrailingPE | 15.92 |
| ForwardPE | 10.87 |
| PriceToSalesRatioTTM | 2.548 |
| PriceToBookRatio | 1.369 |
| EVToRevenue | 2.737 |
| EVToEBITDA | 9.41 |
| Beta | 0.128 |
| 52WeekHigh | 185.17 |
| 52WeekLow | 110.04 |
| 50DayMovingAverage | 162.45 |
| 200DayMovingAverage | 139.93 |
| SharesOutstanding | 146702000 |
| SharesFloat | 146262000 |
| PercentInsiders | 0.152 |
| PercentInstitutions | 95.985 |
| ExDividendDate | None |
| dateChecked | 2025-12-21 23:26:11 |
| fresh | 1 |